Pertuzumab
Pertuzumab (2C4, prodajno ime Perjeta) monoklonalno antitelo je za tretman HER2-positivnog raka dojke. On se koristi u kombinaciji sa trastuzumabom i docetakselom.[2] Ovaj lek je privi u klasi agenasa zvanih „HER dimerizacini inhibitori“. Vezivanjem za HER2, on inhibira dimerizaciju HER2 sa drugim HER receptorima, i smatra se da to dovodi do usporavanja rasta tumora.[3] FDA je odobrila pertuzumab za lečenje HER2-pozitivnog metastatičkog raka dojke u junu 2012.[4][5][6][7]
| |
| Klinički podaci | |
|---|---|
| AHFS/Drugs.com | Monografija |
| Identifikatori | |
| CAS broj | 380610-27-5 |
| ATC kod | L01XC13 |
| DrugBank | DB06366 |
| ChEMBL[1] | CHEMBL2007641  |
| Hemijski podaci | |
| Formula | ? |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 18 dana |
| Farmakoinformacioni podaci | |
| Trudnoća | ? |
| Pravni status | |
| Način primene | Intravenozno |
Reference uredi
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ Pertuzumab
- ↑ de Bono, Johann S.; Bellmunt, J; Attard, G; Droz, JP; Miller, K; Flechon, A; Sternberg, C; Parker, C i dr.. (2007-01-20). „Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer”. Journal of Clinical Oncology 25 (3): 257–262. DOI:10.1200/JCO.2006.07.0888. PMID 17235043.
- ↑ "FDA Approves Perjeta (Pertuzumab) for People With HER2-Positive Metastatic Breast Cancer" (Press release). Genentech. Retrieved 2012-06-09.
- ↑ Protein sequence Link:www.freepatentsonline.com/20110117097.pdf
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682.
- ↑ David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412.
Literatura uredi
- Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
- Thomas L. Lemke, David A. Williams, ur. (2007). Foye's Principles of Medicinal Chemistry (6 izd.). Baltimore: Lippincott Willams & Wilkins. ISBN 0-7817-6879-9.
